PW MEDTECH GROUP DL-0001 (PWE) - Net Assets
Based on the latest financial reports, PW MEDTECH GROUP DL-0001 (PWE) has net assets worth €4.85 Billion EUR (≈ $5.67 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€5.24 Billion ≈ $6.12 Billion USD) and total liabilities (€381.52 Million ≈ $446.04 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See PW MEDTECH GROUP DL-0001 (PWE) balance sheet quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €4.85 Billion |
| % of Total Assets | 92.71% |
| Annual Growth Rate | 6.36% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 9.12 |
PW MEDTECH GROUP DL-0001 - Net Assets Trend (2021–2025)
This chart illustrates how PW MEDTECH GROUP DL-0001's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of PW MEDTECH GROUP DL-0001.
Annual Net Assets for PW MEDTECH GROUP DL-0001 (2021–2025)
The table below shows the annual net assets of PW MEDTECH GROUP DL-0001 from 2021 to 2025. Also explore PWE net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €4.85 Billion ≈ $5.67 Billion |
+1.05% |
| 2024-12-31 | €4.80 Billion ≈ $5.62 Billion |
-0.45% |
| 2023-12-31 | €4.82 Billion ≈ $5.64 Billion |
+4.04% |
| 2022-12-31 | €4.64 Billion ≈ $5.42 Billion |
+22.29% |
| 2021-12-31 | €3.79 Billion ≈ $4.43 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to PW MEDTECH GROUP DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 11.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €2.14 Billion | 54.20% |
| Other Components | €1.81 Billion | 45.80% |
| Total Equity | €3.95 Billion | 100.00% |
PW MEDTECH GROUP DL-0001 Competitors by Market Cap
The table below lists competitors of PW MEDTECH GROUP DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Prodia Widyahusada Tbk PT
JK:PRDA
|
$152.17 Million |
|
Shinhan Seobu T&D REIT Co Ltd
KO:404990
|
$152.25 Million |
|
Paragon Care Ltd
AU:PGC
|
$152.26 Million |
|
CONPET SA
RO:COTE
|
$152.27 Million |
|
Major Cineplex Group Public Company Limited
BK:MAJOR
|
$152.05 Million |
|
ALM Equity AB Pfd.
ST:ALM-PREF
|
$152.03 Million |
|
Koenig & Bauer AG
XETRA:SKB
|
$152.03 Million |
|
ABC Taiwan Electronics
TWO:3236
|
$152.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PW MEDTECH GROUP DL-0001's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,971,401,000 to 3,950,475,000, a change of -20,926,000 (-0.5%).
- Net income of 94,374,000 contributed positively to equity growth.
- Dividend payments of 130,354,000 reduced retained earnings.
- Share repurchases of 19,759,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €94.37 Million | +2.39% |
| Dividends Paid | €130.35 Million | -3.3% |
| Share Repurchases | €19.76 Million | -0.5% |
| Other Changes | €34.81 Million | +0.88% |
| Total Change | €- | -0.53% |
Book Value vs Market Value Analysis
This analysis compares PW MEDTECH GROUP DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €2.42 | €0.09 | x |
| 2022-12-31 | €2.52 | €0.09 | x |
| 2023-12-31 | €2.58 | €0.09 | x |
| 2024-12-31 | €2.67 | €0.09 | x |
| 2025-12-31 | €2.68 | €0.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PW MEDTECH GROUP DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.39%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.46%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.33x
- Recent ROE (2.39%) is below the historical average (6.43%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 19.49% | 272.34% | 0.07x | 1.03x | €359.88 Million |
| 2022 | 2.69% | 19.75% | 0.11x | 1.26x | €-288.48 Million |
| 2023 | 3.79% | 22.69% | 0.13x | 1.27x | €-251.25 Million |
| 2024 | 3.80% | 19.61% | 0.15x | 1.30x | €-246.36 Million |
| 2025 | 2.39% | 11.46% | 0.16x | 1.33x | €-300.67 Million |
Industry Comparison
This section compares PW MEDTECH GROUP DL-0001's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $5,770,613,218
- Average return on equity (ROE) among peers: 4.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PW MEDTECH GROUP DL-0001 (PWE) | €4.85 Billion | 19.49% | 0.08x | $152.10 Million |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $692.18 Million | 21.94% | 0.78x | $2.39 Billion |
| RENAU.UNSP.ARD 1/5 EO-20 (56S0) | $2.51 Billion | 34.85% | 1.01x | $17.02 Billion |
| MEDIMI AB AK (79T) | $15.25 Million | -101.01% | 0.19x | $365.27K |
| TEVANO SYSTEMS HLDGS INC. (7RBA) | $-736.70K | 0.00% | 0.00x | $210.67K |
| STEVANATO GROUP SPA O.N. (87N) | $841.66 Million | 15.96% | 0.69x | $1.05 Billion |
| Carl Zeiss Meditec AG (AFX) | $2.17 Billion | 13.36% | 0.40x | $2.23 Billion |
| CARL ZEISS MEDITEC ADR 1 (AFXA) | $2.17 Billion | 13.36% | 0.40x | $2.14 Billion |
| Bio-gate AG (BIG1) | $3.77 Million | -14.43% | 0.38x | $7.12 Million |
| COLOPLAST SP.ADR 1/10 DK1 (CBH) | $8.29 Billion | 56.75% | 3.52x | $12.73 Billion |
| ESSILORLUXOTTICA 1/2/O.N. (ESLC) | $41.00 Billion | 5.75% | 0.57x | $78.07 Billion |
About PW MEDTECH GROUP DL-0001
PW Medtech Group Limited, an investment holding company, operates as a medical device company in China, India, the Americas, Africa, and internationally. It operates through three segments: Infusion Set Business; Blood Purification Business; and Regenerative Medical Biomaterials Business. The company manufactures and sells infusion sets, such as non-PVC-based infusion sets, precision filter infus… Read more